| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2537338 | European Journal of Pharmacology | 2006 | 17 Pages |
Abstract
Twenty five years after the structure elucidation of slow reacting substance of anaphylaxis, antileukotrienes are established as a new therapeutic modality in asthma. The chapter reviews the biochemistry and pharmacology of leukotrienes and antileukotrienes with particular focus on the different usage of antileukotrienes for treatment of asthma and rhinitis in Europe and the US. Further research needs and new areas for leukotriene involvement in respiratory diseases are also discussed.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Sven-Erik Dahlén,